Fungal colpitis is the most common inflammatory disease of the vagina, whose proportion in the different groups of the patients ranges from 30% to 60%. The major cause is genus Candida. In 80% to 95% of the cases the reason is Candida albicans species and in 10% to 20%--the representatives of the species Candida Non-albicans. One problem that arises in this genital infection is the insufficient effectiveness of the drug treatment in many of the cases.This study is a prospective and monitors 40 non-pregnant women, accounting therapeutic effect of Itraconazol in fungal colpitis. Patients had administered treatment with Itraconazol 2 x 200 mg/1 day, per oral. Microbiological testing was performed prior to the treatment and 2 to 4 weeks after completion of the therapy. We found C. albicans in 75% of the cases and in 25%--C. non-albicans (C. glabrata, C. kefyr, C. krusei, C. famata). In the group of C. albicans, good therapeutic efficiency was observed in 93.3% of the cases, while in patients with C. non-albicans it was in 80% of the cases.Itraconazol showed sufficiently high therapeutic effect for patients with fungal colpitis, it proved to be suitable for patients with Candida albicans and also in the cases with Candida non-albicans.